Updates are available Correction dated 2022-06-23
Click to view Correction: https://doi.org/10.1038/s41575-022-00650-6
-
Authors
Cani, Patrice D. https://orcid.org/0000-0003-2040-2448
Depommier, Clara https://orcid.org/0000-0002-0621-9383
Derrien, Muriel https://orcid.org/0000-0001-8841-9153
Everard, Amandine https://orcid.org/0000-0001-8925-8144
de Vos, Willem M. https://orcid.org/0000-0002-0273-3166
- License Information
-
More Information
Article History
Accepted: 5 May 2022
First Online: 31 May 2022
Change Date: 23 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41575-022-00650-6
Competing interests
: P.D.C., A.E. and W.M.dV. are inventors on patent applications dealing with the use of <i>Akkermansia</i><i>muciniphila</i> and its components in the treatment of metabolic disorders. P.D.C. and W.M.dV. are co-founders of A-Mansia biotech. M.D. is an employee at Danone Nutricia Research. P.D.C. is co-founder of Enterosys. W.M.dV. is co-founder of Caelus Health and named inventor on patents on the use of <i>Eubacterium hallii</i>. C.D. declares no competing interests.
